Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells

Cytokine

Volumn 75, Issue 1, 2015, Pages 151-158

  Kim, Sangmin ^a   Lee, Jeongmin ^a   Jeon, Myeongjin ^a,b   Nam, Seok Jin ^a   Lee, Jeong Eon ^a,b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Cell invasion; Cell migration; Epithelial mesenchymal transition; TGF ; Triple negative breast cancer

Indexed keywords

FIBRONECTIN; MESSENGER RNA; RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UVOMORULIN; VIMENTIN; LY2109761; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; SNAIL FAMILY TRANSCRIPTION FACTORS; TGFB1 PROTEIN, HUMAN; TGFB2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL; CELL CYCLE; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING; BREAST NEOPLASMS; CELL MOTION; CHEMISTRY; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; TUMOR INVASION; WOUND HEALING;

GASTROPODA;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; PYRAZOLES; PYRROLES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRIPLE NEGATIVE BREAST NEOPLASMS; VIMENTIN; WOUND HEALING;

EID: 84938746615     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.05.020     Document Type: Article

References (35)

1. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
2. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
3. Carey L.A. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2011, 16(Suppl 1):71-78.
4. Cancello G., Maisonneuve P., Rotmensz N., Viale G., Mastropasqua M.G., Pruneri G., et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 2010, 21:1974-1981.
5. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434.
6. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281.
7. Podo F., Buydens L.M., Degani H., Hilhorst R., Klipp E., Gribbestad I.S., et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010, 4:209-229.
8. Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor beta in human disease. N Engl J Med 2000, 342:1350-1358.
9. Feng X.H., Derynck R. Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol 2005, 21:659-693.
10. Ghellal A., Li C., Hayes M., Byrne G., Bundred N., Kumar S. Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res 2000, 20:4413-4418.
11. Ikushima H., Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010, 10:415-424.
12. Ewart-Toland A., Chan J.M., Yuan J., Balmain A., Ma J. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomark Preven 2004, 13:759-764.
13. Nam J.S., Suchar A.M., Kang M.J., Stuelten C.H., Tang B., Michalowska A.M., et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006, 66:6327-6335.
14. Yilmaz M., Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res 2010, 8:629-642.
15. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
16. Gregory P.A., Bracken C.P., Smith E., Bert A.G., Wright J.A., Roslan S., et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011, 22:1686-1698.
17. Moustakas A., Heldin C.H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007, 98:1512-1520.
18. Kim S., Lee Y., Seo J.E., Cho K.H., Chung J.H. Caveolin-1 increases basal and TGF-beta1-induced expression of type I procollagen through PI-3 kinase/Akt/mTOR pathway in human dermal fibroblasts. Cell Signal 2008, 20:1313-1319.
19. Micalizzi D.S., Farabaugh S.M., Ford H.L. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010, 15:117-134.
20. Thuault S., Valcourt U., Petersen M., Manfioletti G., Heldin C.H., Moustakas A. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 2006, 174:175-183.
21. Mishra L., Derynck R., Mishra B. Transforming growth factor-beta signaling in stem cells and cancer. Science 2005, 310:68-71.
22. Sullivan N.J., Sasser A.K., Axel A.E., Vesuna F., Raman V., Ramirez N., et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947.
23. Yamashita N., Tokunaga E., Kitao H., Hisamatsu Y., Taketani K., Akiyoshi S., et al. Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol 2013, 139:739-746.
24. Katz L.H., Li Y., Chen J.S., Munoz N.M., Majumdar A., Chen J., et al. Targeting TGF-beta signaling in cancer. Exp Opin Ther Targets 2013, 17:743-760.
25. Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007, 1:84-96.
26. Dumont N., Arteaga C.L. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 2003, 3:531-536.
27. Jatoi I., Anderson W.F., Jeong J.H., Redmond C.K. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 2011, 29:2301-2304.
28. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
29. Wu Y., Zhou B.P. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010, 102:639-644.
30. Vitali R., Mancini C., Cesi V., Tanno B., Mancuso M., Bossi G., et al. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models. Clin Cancer Res 2008, 14:4622-4630.
31. Moody S.E., Perez D., Pan T.C., Sarkisian C.J., Portocarrero C.P., Sterner C.J., et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005, 8:197-209.
32. Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129.
33. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
34. Piek E., Moustakas A., Kurisaki A., Heldin C.H., ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999, 112(Pt 24):4557-4568.
35. Valcourt U., Kowanetz M., Niimi H., Heldin C.H., Moustakas A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 2005, 16:1987-2002.